Ticagrelor (P2Y12 antagonist) has faster offset of antiplatelet activity than clopidogrel, making it preferable when urgent surgery is anticipated. This pharmacological difference is because:

• A Ticagrelor has a shorter half-life and is metabolized faster by hepatic CYP3A4 than clopidogrel
• B Ticagrelor also inhibits ADP release from dense granules limiting its own duration of action
• C Ticagrelor's effect reverses when plasma drug levels fall below IC50 since platelets can synthesize new P2Y12
• D Ticagrelor is a reversible, direct-acting P2Y12 antagonist while clopidogrel requires CYP-mediated activation and irreversibly modifies P2Y12 ✓

Explanation

Clopidogrel is an irreversible thienopyridine prodrug requiring hepatic CYP2C19 and CYP3A4 activation to the active thiol metabolite that permanently alkylates the P2Y12 receptor; platelet function recovers only as new platelets form (5-7 days). Ticagrelor is a direct-acting, reversible cyclopentyl-triazolopyrimidine that binds P2Y12 non-covalently; when plasma ticagrelor falls below effective concentrations, receptor binding reverses. Thus platelet function recovers in 3-5 days rather than 5-7 days, which is clinically important for surgical planning.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.